S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
NASDAQ:RYTM

Rhythm Pharmaceuticals - RYTM Stock Forecast, Price & News

$21.80
+1.86 (+9.33%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$19.88
$22.89
50-Day Range
$3.17
$22.65
52-Week Range
$3.04
$24.44
Volume
1.30 million shs
Average Volume
3.25 million shs
Market Capitalization
$1.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.44

Rhythm Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
30.5% Upside
$28.44 Price Target
Short Interest
Bearish
16.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.80
Upright™ Environmental Score
News Sentiment
0.59mentions of Rhythm Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$41,315 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.82) to ($3.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

589th out of 1,135 stocks

Pharmaceutical Preparations Industry

299th out of 557 stocks

RYTM stock logo

About Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Rhythm Pharmaceuticals Price Performance

RYTM traded up $1.86 on Friday, hitting $21.80. The company had a trading volume of 1,304,440 shares, compared to its average volume of 3,245,926. The stock has a fifty day simple moving average of $9.12 and a 200-day simple moving average of $8.05. The firm has a market capitalization of $1.11 billion, a P/E ratio of -6.25 and a beta of 2.53. Rhythm Pharmaceuticals has a 52-week low of $3.04 and a 52-week high of $24.44.

Analyst Upgrades and Downgrades

Several analysts have weighed in on RYTM shares. Bank of America upgraded Rhythm Pharmaceuticals from an "underperform" rating to a "neutral" rating and boosted their price objective for the company from $8.00 to $20.00 in a research report on Friday, August 5th. Needham & Company LLC dropped their price target on shares of Rhythm Pharmaceuticals from $40.00 to $25.00 and set a "buy" rating for the company in a research report on Friday, June 17th. Wells Fargo & Company raised their price target on shares of Rhythm Pharmaceuticals from $22.00 to $35.00 in a report on Tuesday, August 2nd. Morgan Stanley upped their price objective on shares of Rhythm Pharmaceuticals from $8.00 to $16.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 3rd. Finally, The Goldman Sachs Group raised Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $28.00 target price on the stock in a research note on Sunday, August 7th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, Rhythm Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $28.44.

Insider Transactions at Rhythm Pharmaceuticals

In related news, CFO Hunter C. Smith sold 7,547 shares of the company's stock in a transaction on Friday, July 1st. The stock was sold at an average price of $4.08, for a total value of $30,791.76. Following the sale, the chief financial officer now directly owns 57,614 shares of the company's stock, valued at $235,065.12. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 3.80% of the company's stock.

Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Stock News Headlines

Can Rhythm Pharmaceuticals Keep Up This Tempo?
What 7 Analyst Ratings Have To Say About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Up 7%
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up to $11.56
See More Headlines
Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Company Calendar

Last Earnings
11/02/2021
Today
8/13/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RYTM
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.44
High Stock Price Forecast
$37.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+30.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$-69,610,000.00
Net Margins
-1,310.60%
Pretax Margin
-1,437.26%

Debt

Sales & Book Value

Annual Sales
$3.15 million
Book Value
$3.86 per share

Miscellaneous

Free Float
48,794,000
Market Cap
$1.11 billion
Optionable
Optionable
Beta
2.53

Key Executives

  • Dr. David P. Meeker M.D. (Age 68)
    Chairman, Pres & CEO
    Comp: $1.09M
  • Mr. Hunter C. Smith M.B.A. (Age 53)
    CFO & Treasurer
    Comp: $658.21k
  • Mr. Joseph Shulman (Age 47)
    Chief Technical Officer
    Comp: $555.66k
  • Mr. Yann Mazabraud (Age 49)
    Exec. VP & Head of International
    Comp: $693.62k
  • Ms. Jennifer L. Chien (Age 47)
    Exec. VP & Head of North America
    Comp: $597.46k
  • Mr. William T. Roberts (Age 43)
    Chief Accounting Officer
  • Mr. David Connolly
    Head of Investor Relations & Corp. Communications
  • Mr. Jim Flaherty
    Sr. VP & Gen. Counsel
  • Ms. Sarah Ryan
    VP of Sales & Marketing
  • Ms. Pamela J. Cramer (Age 48)
    Chief HR Officer













RYTM Stock - Frequently Asked Questions

Should I buy or sell Rhythm Pharmaceuticals stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RYTM shares.
View RYTM analyst ratings
or view top-rated stocks.

What is Rhythm Pharmaceuticals' stock price forecast for 2022?

8 brokers have issued 1 year target prices for Rhythm Pharmaceuticals' stock. Their RYTM share price forecasts range from $16.00 to $37.00. On average, they predict the company's stock price to reach $28.44 in the next twelve months. This suggests a possible upside of 30.5% from the stock's current price.
View analysts price targets for RYTM
or view top-rated stocks among Wall Street analysts.

How have RYTM shares performed in 2022?

Rhythm Pharmaceuticals' stock was trading at $9.98 at the beginning of 2022. Since then, RYTM stock has increased by 118.4% and is now trading at $21.80.
View the best growth stocks for 2022 here
.

When is Rhythm Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our RYTM earnings forecast
.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its earnings results on Tuesday, November, 2nd. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.13. The firm had revenue of $1.03 million for the quarter. Rhythm Pharmaceuticals had a negative trailing twelve-month return on equity of 67.73% and a negative net margin of 1,310.60%. During the same period in the previous year, the business earned ($0.77) EPS.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Primecap Management Co. CA (12.55%), Assenagon Asset Management S.A. (1.37%), FMR LLC (1.10%), Rice Hall James & Associates LLC (0.32%), Northern Trust Corp (0.22%) and SG Americas Securities LLC (0.16%). Insiders that own company stock include David P Meeker, Hunter C Smith, Joseph Shulman, Nithya Desikan, Pamela J Cramer, Ra Capital Management, LP, Todd Foley, William T Roberts and Yann Mazabraud.
View institutional ownership trends
.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $21.80.

How much money does Rhythm Pharmaceuticals make?

Rhythm Pharmaceuticals (NASDAQ:RYTM) has a market capitalization of $1.11 billion and generates $3.15 million in revenue each year. The company earns $-69,610,000.00 in net income (profit) each year or ($3.49) on an earnings per share basis.

How many employees does Rhythm Pharmaceuticals have?

The company employs 140 workers across the globe.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The official website for the company is www.rhythmtx.com. The company can be reached via phone at (857) 264-4280, via email at hannah.deresiewicz@sternir.com, or via fax at 857-264-4299.

This page (NASDAQ:RYTM) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.